Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor
- PMID: 15757907
- DOI: 10.1074/jbc.M410834200
Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor
Abstract
Changes in receptor conformation are believed to be key for ligand-induced regulation of cellular signaling cascades. However, little information exists about specific conformations of a receptor. We recently applied fluorescence resonance energy transfer to determine distances from distinct points distributed over the surface and within the helical bundle of the cholecystokinin receptor to the amino terminus of a full agonist CCK analogue (Harikumar, K. G., Pinon, D. I., Wessels, W. S., Dawson, E. S., Lybrand, T. P., Prendergast, F. G., and Miller, L. J. (2004) Mol. Pharmacol. 65, 28-35). Here, we apply the same experimental strategy to determine distances from the same receptor positions to an analogous point at the amino terminus of structurally related partial agonist (Alexa488-Gly-[(Nle(28,31))CCK-26-32]phenethyl ester) and antagonist (Alexa488-Gly-[(D-Trp31, Nle(28,31))CCK-26-32]phenethyl ester) ligands. A high degree of spectral overlap and fluorescence transfer was observed for ligand-occupied fluorescent-tagged receptors with no transfer observed for the ligand-occupied pseudo-wild type null cysteine-reactive mutant receptor (C94S). For the partial agonist, calculated distances to receptor positions 94, 102, 204, and 341, representing sites within the helical confluence, and the first, second, and third loops, were 21 +/- 0.4, 18 +/- 0.4, 25 +/- 1, and 17 +/- 1 angstroms, not different from those measured previously for the analogous full agonist. For the antagonist, the analogous distances were 21 +/- 2, 28 +/- 2, 15 +/- 1 and 21 +/- 1 angstroms. Distances to the first and third loops were longer and the distance to the second loop was shorter for the antagonist relative to both the full and partial agonist probes, whereas all three probes demonstrated similar distances to the intrahelical reference point. This supports the possibilities of changes in the conformation of the probe and/or the receptor induced by structurally similar ligands having distinct intrinsic biological activities.
Similar articles
-
Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.J Biol Chem. 2005 Jan 14;280(2):1044-50. doi: 10.1074/jbc.M409480200. Epub 2004 Nov 1. J Biol Chem. 2005. PMID: 15520004
-
Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.Mol Pharmacol. 2004 Jan;65(1):28-35. doi: 10.1124/mol.65.1.28. Mol Pharmacol. 2004. PMID: 14722234
-
Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.Biochemistry. 2008 Sep 9;47(36):9574-81. doi: 10.1021/bi800734w. Epub 2008 Aug 13. Biochemistry. 2008. PMID: 18700727 Free PMC article.
-
Characterization of the type A cholecystokinin receptor hormone-binding domain: use of contrasting and complementary methodologies.Peptides. 2001 Aug;22(8):1223-8. doi: 10.1016/s0196-9781(01)00445-4. Peptides. 2001. PMID: 11457514 Review.
-
Applications of fluorescence in the characterization of the ligand-binding domain and activation of the cholecystokinin receptor.Pharmacol Toxicol. 2002 Dec;91(6):286-9. doi: 10.1034/j.1600-0773.2002.910604.x. Pharmacol Toxicol. 2002. PMID: 12688370 Review.
Cited by
-
Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements.Biophys J. 2008 Aug;95(4):2086-96. doi: 10.1529/biophysj.108.133371. Epub 2008 May 16. Biophys J. 2008. PMID: 18487307 Free PMC article.
-
Fluorescence polarization screening for allosteric small molecule ligands of the cholecystokinin receptor.Assay Drug Dev Technol. 2011 Aug;9(4):394-402. doi: 10.1089/adt.2010.0310. Epub 2011 Mar 11. Assay Drug Dev Technol. 2011. PMID: 21395402 Free PMC article.
-
Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor.EJNMMI Res. 2018 Apr 16;8(1):33. doi: 10.1186/s13550-018-0387-3. EJNMMI Res. 2018. PMID: 29663167 Free PMC article.
-
Structural basis of cholecystokinin receptor binding and regulation.Pharmacol Ther. 2008 Jul;119(1):83-95. doi: 10.1016/j.pharmthera.2008.05.001. Epub 2008 May 11. Pharmacol Ther. 2008. PMID: 18558433 Free PMC article. Review.
-
Sensitivity of cholecystokinin receptors to membrane cholesterol content.Front Endocrinol (Lausanne). 2012 Oct 18;3:123. doi: 10.3389/fendo.2012.00123. eCollection 2012. Front Endocrinol (Lausanne). 2012. PMID: 23087674 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources